文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

新辅助雄激素剥夺治疗对高级别前列腺癌肿瘤缺氧的影响:18F-MISO PET-MRI研究

The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-03-08

结果显示7例患者基线18F-MISO摄取显著,TBR与Gleason评分相关;nADT后仅高级别病灶和基线显著摄取区域的TBR显著下降,提示nADT可能改善缺氧。

要点

  • 18F-MISO PET-MRI可在部分高级别前列腺癌中检出缺氧区域。
  • 基线18F-MISO TBR与Gleason评分显著相关。
  • 3个月nADT后高级别病灶18F-MISO TBR显著下降。

核心结论

  • 18F-MISO PET显像在前列腺癌中摄取可变,与较高Gleason评分相关,高级别病灶在3个月nADT后TBR显著降低,提示存在缺氧微环境及nADT的复氧效应。

研究设计与样本

  • 诊断时行18F-FCH PET-CT,nADT前行18F-MISO hybrid PET-MRI,3个月后复查18F-MISO PET-MRI(1例因不依从nADT退出)。
  • 对最高Gleason评分病灶行缺氧和增殖相关生物标志物免疫组化,采用非参数检验分析。

主要发现

  • 7例患者基线18F-MISO摄取显著,其中5例与最高Gleason评分区域一致。
  • 基线Gleason评分与18F-MISO TBR显著相关,18F-MISO TBR与MRI灌注标志物显著相关。
  • 基线Gleason评分与18F-FCH SUVmax、Gleason评分与PIRADS评分、18F-FCH SUVmax与PIRADS评分均显著相关。
  • 18F-MISO阳性和阴性活检标本之间组织生物标志物无差异。
  • nADT后18F-MISO TBR仅在高级别病灶和基线显著摄取区域显著下降。

关键数值与推荐

  • 18F-MISO阳性区域定义为肿瘤本底比(TBR)≥1.4。
  • 纳入标准为Gleason评分≥8的前列腺癌患者。
  • nADT持续3个月后复查18F-MISO PET-MRI。

临床怎么用

  • 18F-MISO PET-MRI可用于评估高级别前列腺癌的肿瘤缺氧。
  • nADT后复查18F-MISO PET-MRI可观察高级别病灶的复氧变化。
  • 缺氧显像与Gleason评分、灌注标志物及PIRADS评分相关,可作为综合评估参考。

局限性

  • 1例患者因不依从nADT退出,未完成第二次18F-MISO PET-MRI。
  • 18F-MISO阳性和阴性标本间组织生物标志物无差异,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor hypoxia is associated with radioresistance and poor prognosis after radiation therapy for prostate cancer (PCa). In this prospective pilot study, we assessed the ability of 18F-misonidazole (18F-MISO) positron emission tomography (PET)-magnetic resonance imaging (MRI) to detect hypoxia in high-grade PCa patients who were candidates for curative radiation therapy, and we evaluated 18F-MISO PET-MRI modulation after 3 months of neoadjuvant androgen deprivation therapy (nADT). METHODS AND MATERIALS: Eleven PCa patients with a Gleason score (GS) ≥ 8 underwent 18F-fluorocholine (18F-FCH) PET-computed tomography at diagnosis and an 18F-MISO hybrid PET-MRI examination before nADT; a second 18F-MISO PET-MRI examination was acquired after 3 months of nADT for all patients but one who dropped out because of noncompliance with nADT. Immunohistochemistry for tissue hypoxia- and proliferation-related biomarkers (glucose transporter 1, carbonic anhydrase IX, vascular endothelial growth factor A, Ki-67, hypoxia-inducible factor 1 alpha, and epidermal growth factor receptor) was performed in lesions bearing the highest GS. We used nonparametric tests to assess (1) the presence of 18F-MISO-positive regions (tumor-to-background ratio [TBR] ≥ 1.4) at baseline; (2) the correlation between imaging parameters (PET tracer uptake, Prostate Imaging Reporting and Data System [PIRADS] scores, and dynamic contrast enhancement perfusion markers) at baseline; (3) the difference in immunohistochemistry staining between 18F-MISO-positive and -negative lesions; and (4) the changes in 18F-MISO PET-MRI after nADT. RESULTS: Uptake of 18F-MISO was significant in 7 patients, being coincidental with the highest GS region in 5 of them. A significant correlation was found at baseline between GS and 18F-MISO TBR, between 18F-MISO TBR and MRI perfusion markers, between GS and 18F-FCH maximum standardized uptake value, between GS and PIRADS score, and between 18F-FCH maximum standardized uptake value and PIRADS score. No difference was found between 18F-MISO-positive and -negative biopsy specimens with respect to tissue biomarkers. The TBR of 18F-MISO diminished significantly after nADT only in high-grade lesions and in regions with a significant uptake at baseline. CONCLUSIONS: PET imaging with 18F-MISO showed variable uptake in PCa, associated with a higher GS, lowering significantly after 3 months of nADT in high-grade lesions. These results suggest the existence of a hypoxic microenvironment in PCa and a reoxygenation effect of nADT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mainta IC, Zilli T, Tille JC, et al. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study. Int J Radiat Oncol Biol Phys. 2018. PMID: 29678527. doi:10.1016/j.ijrobp.2018.02.170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。